Bank of America says it spends about $250 million per year on GLP-1 medications for its employees, according to remarks by its CEO reported by NDTV and CNBC. The statement comes as demand for GLP-1 drugs such as Ozempic and Wegovy continues to rise in the United States. Sources note that these medications can cost thousands of dollars per patient annually, which increases overall healthcare spending for employers that offer coverage.
Both outlets describe how higher utilization of GLP-1 treatments is weighing on employer costs. The reporting frames the spending figure as part of the broader financial impact health plans face as more employees seek these therapies. While the articles focus on Bank of America’s reported annual expenditure, they also underscore that the challenge is not unique to one company, with other employers similarly dealing with escalating costs tied to GLP-1 prescriptions. The accounts do not add specific details on eligibility criteria, number of recipients, or contract pricing beyond the overall annual spend.
